233 related articles for article (PubMed ID: 24417979)
21. Increased levels of serum neopterin in attention deficit/hyperactivity disorder (ADHD).
Ceylan MF; Uneri OS; Guney E; Ergin M; Alisik M; Goker Z; Senses Dinc G; Karaca Kara F; Erel O
J Neuroimmunol; 2014 Aug; 273(1-2):111-4. PubMed ID: 24969118
[TBL] [Abstract][Full Text] [Related]
22. The Relationship between Serum Vitamin D Level and Attention Deficit Hyperactivity Disorder.
Sharif MR; Madani M; Tabatabaei F; Tabatabaee Z
Iran J Child Neurol; 2015; 9(4):48-53. PubMed ID: 26664441
[TBL] [Abstract][Full Text] [Related]
23. Increased urinary 6-hydroxymelatoninsulfate levels in attention deficit hyperactivity disorder diagnosed children and adolescent.
Büber A; Çakaloz B; Işıldar Y; Ünlü G; Bostancı HE; Aybek H; Herken H
Neurosci Lett; 2016 Mar; 617():195-200. PubMed ID: 26879834
[TBL] [Abstract][Full Text] [Related]
24. Mean platelet volume in children with attention deficit hyperactivity disorder.
Yorbik O; Mutlu C; Tanju IA; Celik D; Ozcan O
Med Hypotheses; 2014 Mar; 82(3):341-5. PubMed ID: 24485405
[TBL] [Abstract][Full Text] [Related]
25. [The role of zinc in the treatment of hyperactivity disorder in children].
Dodig-Curković K; Dovhanj J; Curković M; Dodig-Radić J; Degmecić D
Acta Med Croatica; 2009 Oct; 63(4):307-13. PubMed ID: 20034331
[TBL] [Abstract][Full Text] [Related]
26. Platelet serotonin concentration in children with attention-deficit/hyperactivity disorder.
Hercigonja Novkovic V; Rudan V; Pivac N; Nedic G; Muck-Seler D
Neuropsychobiology; 2009; 59(1):17-22. PubMed ID: 19221444
[TBL] [Abstract][Full Text] [Related]
27. Incontinence in children with treated attention-deficit/hyperactivity disorder.
Niemczyk J; Equit M; Hoffmann L; von Gontard A
J Pediatr Urol; 2015 Jun; 11(3):141.e1-6. PubMed ID: 25863677
[TBL] [Abstract][Full Text] [Related]
28. Iron deficiency in children with attention-deficit/hyperactivity disorder.
Konofal E; Lecendreux M; Arnulf I; Mouren MC
Arch Pediatr Adolesc Med; 2004 Dec; 158(12):1113-5. PubMed ID: 15583094
[TBL] [Abstract][Full Text] [Related]
29. Serum nerve growth factor (NGF) levels in children with attention deficit/hyperactivity disorder (ADHD).
Guney E; Ceylan MF; Kara M; Tekin N; Goker Z; Senses Dinc G; Ozturk O; Eker S; Kizilgun M
Neurosci Lett; 2014 Feb; 560():107-11. PubMed ID: 24361544
[TBL] [Abstract][Full Text] [Related]
30. Decreased serum orexin A levels in drug-naive children with attention deficit and hyperactivity disorder.
Baykal S; Albayrak Y; Durankuş F; Güzel S; Abbak Ö; Potas N; Beyazyüz M; Karabekiroğlu K; Donma MM
Neurol Sci; 2019 Mar; 40(3):593-602. PubMed ID: 30617449
[TBL] [Abstract][Full Text] [Related]
31. Lipid profile, fatty acid composition and pro- and anti-oxidant status in pediatric patients with attention-deficit/hyperactivity disorder.
Spahis S; Vanasse M; Bélanger SA; Ghadirian P; Grenier E; Levy E
Prostaglandins Leukot Essent Fatty Acids; 2008; 79(1-2):47-53. PubMed ID: 18757191
[TBL] [Abstract][Full Text] [Related]
32. Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder.
Gau SS; Ni HC; Shang CY; Soong WT; Wu YY; Lin LY; Chiu YN
Aust N Z J Psychiatry; 2010 Feb; 44(2):135-43. PubMed ID: 20113302
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
34. Inverse associations between cord vitamin D and attention deficit hyperactivity disorder symptoms: A child cohort study.
Mossin MH; Aaby JB; Dalgård C; Lykkedegn S; Christesen HT; Bilenberg N
Aust N Z J Psychiatry; 2017 Jul; 51(7):703-710. PubMed ID: 27694636
[TBL] [Abstract][Full Text] [Related]
35. Attention deficit hyperactivity disorder in children with primary monosymptomatic nocturnal enuresis: A case-control study.
Yousefichaijan P; Sharafkhah M; Salehi B; Rafiei M
Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):73-80. PubMed ID: 26787570
[TBL] [Abstract][Full Text] [Related]
36. Substance use disorders in adolescents with attention deficit hyperactivity disorder: a 4-year follow-up study.
Groenman AP; Oosterlaan J; Rommelse N; Franke B; Roeyers H; Oades RD; Sergeant JA; Buitelaar JK; Faraone SV
Addiction; 2013 Aug; 108(8):1503-11. PubMed ID: 23506232
[TBL] [Abstract][Full Text] [Related]
37. Neuropeptide Y Levels in Children and Adolescents with Attention Deficit Hyperactivity Disorder.
Hekim Bozkurt Ö; Güney E; Göker Z; Şenses Dinç G; Alışık M; Erel Ö; Çöp E; Üneri ÖŞ
Turk Psikiyatri Derg; 2018; 29(1):31-35. PubMed ID: 29730872
[TBL] [Abstract][Full Text] [Related]
38. Comorbidity and continuity of attention deficit hyperactivity disorder (ADHD) from childhood to adolescence in Turkey.
Cak HT; Dinc GS; Tuzun Z; Evinc SG; Cop E; Cuhadaroglu Cetin F
Atten Defic Hyperact Disord; 2013 Dec; 5(4):353-60. PubMed ID: 23893566
[TBL] [Abstract][Full Text] [Related]
39. Vitamin D's Molecular Action Mechanism in Attention-Deficit/ Hyperactivity Disorder: A Review of Evidence.
Saedisomeolia A; Samadi M; Gholami F; Seyedi M; Effatpanah M; Hashemi R; Abdolahi M; Honarvar NM
CNS Neurol Disord Drug Targets; 2018; 17(4):280-290. PubMed ID: 29714151
[TBL] [Abstract][Full Text] [Related]
40. Comparison of serum vitamin D levels between healthy and ADHD children.
Massoodi A; Javadian Koutanaei S; Faraz Z; Geraili Z; Zavarmousavi SM
Caspian J Intern Med; 2023; 14(4):681-686. PubMed ID: 38024166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
